Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.
about
Nitric oxide releasing nanoparticles are therapeutic for Staphylococcus aureus abscesses in a murine model of infectionTobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TBIssues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MICTime-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeaeGenetic Resistance Determinants, In Vitro Time-Kill Curve Analysis and Pharmacodynamic Functions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeaeAn investigation of exudative epidermitis (greasy pig disease) and antimicrobial resistance patterns of Staphylococcus hyicus and Staphylococcus aureus isolated from clinical cases.Bactericidal efficacy of nitric oxide-releasing silica nanoparticles.Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infectionA Diffusion-Based and Dynamic 3D-Printed Device That Enables Parallel in Vitro Pharmacokinetic Profiling of MoleculesAntibiotic dosing in critical illness.Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin.In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin.Protein binding and antimicrobial activity of ceftriaxone: comparative assessments by gradient plate technique and time-kill study.The kinetic profile of gentamicin in premature neonates.
P2860
Q33516015-7ED0CF5B-0BCD-4233-BA16-7D4758F6DF29Q34476089-8FB2D113-28E8-442A-A949-A6F700A50194Q34591451-6B8150F9-B5E5-45F9-9C37-7DA895A8F960Q35637864-2A69D8FB-E8AB-4AC1-9FCD-71EE7232931DQ36136318-8DB5F6E4-BA37-4DF6-BA6D-B0D82C9104A4Q36360329-BC99D1E2-66FA-42F3-B739-F45CF55BFDE1Q36555484-8C774A09-5E2F-475C-AB7A-6BFE81A51857Q36606353-8C759921-6FB5-4EC4-825B-2786E0AC1411Q36879791-E9A06D89-FA01-4A55-B715-23DCBD393BF9Q37630801-CDDBCCB1-592D-414D-B431-975AF53CEF93Q37852466-120020FF-40DE-4A69-88F0-F7A3CB406DFFQ39477892-B8FC3317-B6AE-4AF9-9CB3-C488B437459DQ43744039-A70D679D-9830-46C1-B3E5-5C5713405C02Q45257437-F169722E-C119-44D6-957A-C42AC6B3E43CQ52163802-841D1E51-45C5-4BC3-A92A-D52C970F49B5
P2860
Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Achieving an optimal outcome i ...... acodynamics of antimicrobials.
@ast
Achieving an optimal outcome i ...... acodynamics of antimicrobials.
@en
type
label
Achieving an optimal outcome i ...... acodynamics of antimicrobials.
@ast
Achieving an optimal outcome i ...... acodynamics of antimicrobials.
@en
prefLabel
Achieving an optimal outcome i ...... acodynamics of antimicrobials.
@ast
Achieving an optimal outcome i ...... acodynamics of antimicrobials.
@en
P2093
P1476
Achieving an optimal outcome i ...... acodynamics of antimicrobials.
@en
P2093
P356
10.2165/00003088-199937010-00001
P577
1999-07-01T00:00:00Z
P6179
1050139303